ACAD · ACADIA Pharmaceuticals Inc.

📣 What ACAD Says Is Next

• this year · “As we look ahead, we remain focused on advancing our deep, differentiated pipeline, with remlifanserin representing a key value driver as we approach expected Phase 2 topline data in Alzheimer’s disease psychosis later this year.”
  Company press release, May 6, 2026 · SEC filing
• the end of 2026 · “After her retirement, Acadia plans to retain Dr. Thompson as a consultant through at least the end of 2026 to ensure scientific and leadership continuity through the planned readout of the Phase 2 clinical study of remlifanserin in Alzheimer’s disease psychosis (ADP) and into early Phase 3 clinical study execution.”
  Company press release, May 1, 2026 · SEC filing
• this year · “Phase 2 top-line results readout from the remlifanserin Alzheimer’s disease psychosis study remains on track for August to October 2026 timeframe, representing a potential catalyst for the Company this year.”
  Company press release, Feb 25, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

• Aug 2027 · Phase 2 · Recruiting · ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
  Registry primary completion date, not a results date
• Jan 2028 · Phase 2/3 · Recruiting · ACP-204 in Adults With Alzheimer's Disease Psychosis
  Registry primary completion date, not a results date
• Feb 2028 · Phase 2 · Recruiting · Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
  Registry primary completion date, not a results date
• Feb 2029 · Phase 3 · Recruiting · Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
  Registry primary completion date, not a results date
• Apr 2029 · Phase 3 · Enrolling · ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
  Registry primary completion date, not a results date
• Oct 2025 · Phase 3 · Active Trial · Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
  Registry date passed, readout not confirmed

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not ACAD's own candidates): Pimavanserin, Quetiapine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACAD holds $956.5M in cash and short-term investments (as of Jun 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

• No operating cash burn in latest filings

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACAD files for a raise →

👥 Who Owns ACAD

Share count 172,305,518 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.